人酸性成纤维细胞生长因子治疗糖尿病足溃疡23例

糖尿病足溃疡是糖尿病的严重并发症之一,是由糖尿病神经病变、周围血管病变及伴随的继发感染所造成的足部溃烂,目前尚无较好的治疗办法.我们采用人酸性成纤维细胞生长因子(haFGF)治疗,取得了满意的疗效,现总结如下.     

慷舒灵治疗糖尿病足溃疡34例

目的：观察慷舒灵治疗糖尿病足溃疡的临床疗效。方法：50例患者随机分为两组,治疗组34例,对照组16例。治疗组在基础治疗方法上应用慷舒灵外敷治疗,对照组则应用凡士林纱条外敷。结果：治疗组34例,治愈20例,显效7例,有效5例,无效2例,总有效率94.1%,住院18 d;对照组16例,治愈3例,显效6例,有效2例,无效5例,总有效率69%,住院30 d。两组总有效率比较差异有统计学意义（P＜0.05）,治疗组缩短了疗程。结论：慷舒灵外敷治疗糖尿病足溃疡有较好疗效。     

中西医结合点状植皮治疗糖尿病足溃疡

目的：观察中西医结合点状植皮法对糖尿病足溃疡的修复作用。方法：在174例糖尿病足溃疡患者创面肉芽组织较新鲜,质地坚实,无明显水肿,分泌物较少,周围无急性炎症时植皮,在局麻下,用锐刀切取点状皮片,将皮片均匀置于创面肉芽组织,使皮片深层与肉芽底部紧密接触,皮片间距0.5--1 cm,无菌网眼纱布覆盖固定,敷以生肌象皮膏纱条,无菌干纱布稍加压包扎。结果：植皮数8--60片,平均成活率80%;创面痊愈时间7--28 d,平均18.7 d。结论：中西医结合点状植皮法治疗糖尿病足溃疡,操作简便,疗效显著,创伤小,不需要特殊技术及设备器械。     

低压力负压治疗糖尿病缺血性足溃疡的临床研究

目的：观察低压力负压治疗中度缺血的糖尿病足溃疡的效果。方法：选择中度缺血的糖尿病足溃疡患者 160 例, 均进行系统的内科治疗。按随机数字表法分为观察组 120 例,对照组 40 例。观察组分为 3 个亚组,分别采用 120 mmHg、90 mmHg、60 mmHg 负压治疗（间歇模式）,每组各 40 例,以比较常规负压治疗与低压力负压治疗的疗效差异。对照组采用常规换药治疗。记录治疗 2 周、4 周后伤口面积、局部症状积分及治疗过程的疼痛评分。结果：治疗 2 周、4 周时,观察组效果优于对照组（P<0.05）;3 个亚组之间,伤口面积和局部症状积分方面无统计学差异（P>0.05）。疼痛评分方面,60 mmHg 负压治疗组疼痛评分最低,2 周时（2.76±2.75）,4 周时（2.25±2.21）;90 mmHg 负压治疗组次之,2 周时（3.75±3.01）,4 周时（3.88±2.59）;120 负压治疗组疼痛评分最高,2 周时（5.13±2.64）,4 周时（4.38±2.92）;差异有统计学意义（P<0.05）。在治疗期间各组不良反应无明显差异（P>0.05）。60 mmHg 负压治疗组为本次研究的最优治疗方案。结论：低压力负压治疗糖尿病缺血性足溃疡,疗效确切,可以有效促进伤口愈合,减轻患者疼痛。     

股前外侧嵌合穿支皮瓣修复糖尿病足溃疡创面

目的:探讨股前外侧嵌合穿支皮瓣对糖尿病足溃疡（DFU）创面修复的临床疗效。方法:2018年1月至2019年12月,共收治14例II型糖尿病足部溃疡,男10例,女4例,年龄49~58岁。其中单纯周围神经病变10例,周围神经病变合并血管病变4例,无单独血管病变患者。在严格控制患者血糖的基础上,对Wagner 2级以上DFU...     

VSD联合股前外侧穿支皮瓣治疗糖尿病足溃疡12例

目的:探讨VSD负压吸引联合股前外侧穿支皮瓣修复糖尿病足溃疡的临床疗效。方法 :回顾性分析2015年6月至2017年12月就诊的糖尿病足12例,男8例,女4例;年龄49～71岁,平均57.4岁;溃疡创面形成时间1～24个月;足背部7例,足趾区5例;溃疡创面面积3 cm×5 cm～7 cm×10 cm。均采用清创VSD负压吸引、中药洗剂冲洗,皮瓣修复治疗,观察皮瓣存活情况、外形、感觉恢复程度。结果:12例患者术后移植皮瓣全部成活,创面修复满意,供区愈合良好。随访6～18个月,12例皮瓣存活良好,皮瓣质地柔软,弹性良好,无明显臃肿,感觉部分恢复。结论:糖尿病足溃疡清创后VSD负压引流联合股前外侧穿支皮瓣移植临床效果满意,值得推广。     

改良胫骨横向骨搬移术治疗糖尿病足溃疡及脉管炎溃疡

目的 报道改良胫骨横向骨搬移术治疗糖尿病足溃疡及脉管炎溃疡的临床应用和疗效。方法2019年6月-2020年9月,收治糖尿病足溃疡8例、脉管炎溃疡1例,采用改良胫骨横向骨搬移术进行治疗。使用大型骨搬移架7例、小型骨搬移架2例。结果 9例手术顺利完成,术后顺利出院,均获得8～23个月的随访,平均13个月。8例溃疡术后顺利愈合,1例有继发感染、坏死,再次行清创术后出现愈合倾向,缓慢愈合。骨搬移时间4～12周,平均6周,溃疡愈合时间1～26周,平均12周。足趾感觉、血运获得改善,未发生皮瓣坏死、骨折、血栓等并发症。结论 改良胫骨横向骨搬移术是治疗糖尿病足溃疡、脉管炎溃疡一种有效方法,并为提高有效率、降低并发症提供了新的思路和理论依据。     

负压封闭引流技术在糖尿病足溃疡治疗中的应用研究

目的：探讨负压封闭引流技术（VSD）治疗糖尿病足溃疡的临床疗效。方法对VSD治疗组和常规治疗组患者进行回顾性分析,记录并比较两组患者在有效清创、控制血糖水平及抗感染等治疗后,使用VSD和常规换药方法直到外科手术的准备时间。结果 VSD治疗组溃疡创面术前准备时间（12.78±3.92）d明显少于常规治疗组（23.00±4.67）d,两组之间的差异有显著性意义（P＜0.001）。结论 VSD治疗相对创面的愈合起到了正性促进作用,是糖尿病足溃疡创面从清创到进行外科手术期间的有效辅助治疗方式。     

胫骨横向骨搬移结合负压引流治疗糖尿病足溃疡的临床疗效分析

目的 :探讨胫骨横向骨搬移微血管网再生技术结合封闭负压引流治疗伴溃疡形成的糖尿病足的临床疗效。方法:对2015年11月至2016年12月采用胫骨横向骨搬移结合负压引流治疗的19例伴溃疡形成的糖尿病足的临床资料进行回顾性分析,男15例,女4例;年龄42~82岁,平均(64.57±7.14)岁;糖尿病平均病程(14.62±6.19)年;左足12例,右足7例;溃疡面积2 cm×3 cm~8 cm×6 cm;按照Texas分类法进行分类,所有病例为D期,其中2级3例,3级10例,4级6例。手术前后测量踝肱指数及密歇根神经体征评分(MNSI)评价患足周围血管和周围神经功能恢复情况,术后复查血管造影或血管彩超。结果:19例患者中17例术后获得随访,时间3~13个月,平均6.9个月。17例患足创面均得到愈合;术后3个月踝肱指数由术前的0.51±0.20升至0.93±0.18,差异有统计学意义(t=13.63,P=0.000);术后3个月的MNSI为5.76±1.44,优于术前的4.06±1.36,差异有统计学意义(t=7.31,P=0.000)。术后复查血管造影或血管彩超显示患足微血管网再生满意,患足功能达到正常运动和日常生活需要。结论:胫骨横向骨搬移微血管网再生技术可以重建患肢小腿以下微血管网,促进周围血管及周围神经恢复,结合封闭负压引流可促进创面愈合,具有手术简便、疗效确切,保肢成功率高的优点,是治疗糖尿病足溃疡的理想方法之一。     

糖尿病足溃疡断层游离皮片植皮术病人的护理

对 30例糖尿病足溃疡断层游离皮片植皮术治疗的病人 ,术前进行细致的心理护理 ,术后做好供皮区及受皮区的观察及处理 ,指导病人患肢功能锻炼及出院后足部自我保健。结果 30例病人植皮术均获得成功 ,平均住院(30 .6± 11.8)d ,术后平均 (14 .3± 5 .2 )d痊愈出院。     

Amputation in diabetic foot ulcer: A treatment dilemma

Diabetic foot is a clinical manifestation of diabetes with a wide range of symptoms, including ulceration, osteomyelitis, osteoarticular destruction, and gangrene, as a consequence of advanced disease. Some diabetic foot cases present general indications for amputation, including dead limb, threat to the patient’s life, pain, loss of function, or nuisance. Various tools have been introduced to help decision-making in amputation for diabetic foot. However, it remains a conundrum because diabetic foot involves multiple pathomechanisms and factors that hinder its outcomes. Sociocultural issues often impede treatment from the patient’s side. We reviewed different perspectives in diabetic foot management, particularly related to amputation. In addition to deciding whether to amputate, physicians should address amputation level, timing, and ways to avoid patient deconditioning. Surgeons should not be autocratic in these circumstances and should be aware of beneficence and maleficence when considering whether to amputate. The main goal should be improving the patients’ quality of life rather than preserving the limb as much as possible.     

糖尿病足部溃疡外科保肢治疗进展

糖尿病足部溃疡是糖尿病的一个严重并发症,占非创伤性截肢的第1位。糖尿病足发病涉及足踝外科、血管外科、内分泌科.、感染控制,治疗方案需多学科联合诊治。清创术是治疗糖尿病足部溃疡的基础,清创过程中须注意维持足部正常解剖结构;负压封闭引流技术以及抗生素骨水泥在外科感染控制、溃烂创面愈合方面优势明显,疗效满意;肌腱延长术可缓解足底部应力集中导致的溃疡发生、进展等,其适应证广泛,优势在于既可预防足部溃疡形成也可治疗溃疡;皮瓣移植虽可以解决创口愈合问题,但是需要考虑移植皮瓣能否承担与足底组织相同的功能;胫骨骨搬运是一项较新的技术,具体机制还不清楚,但从临床疗效看具有一定的应用前景。     

糖尿病足周围血管神经病变的预防和治疗

目的探讨预防和治疗糖尿病足周围血管神经病变的有效措施。方法对我科在1998年5月至2008年5月收治160例糖尿病足周围血管神经病变进行回顾性分析。结果在药物和辅助治疗下,皮肤溃疡组愈合率77％,软组织感染组65％,其余及深部溃疡组手术后愈合率96％。结论积极预防和规范化治疗是处理糖尿病足周围血管神经病变的有效措施。     

Insensate foot of diabetic foot ulcer can have underlying silent neuropathic pain

Subjects with diabetic foot ulcer (DFU) are believed to be less likely to complain of symptoms of painful diabetic peripheral neuropathy (PDPN). When we assessed this using Leeds Assessment of Neuropathic Symptoms and Signs questionnaire (s-LANSS) we found that out of total 44 subjects with DFU, 19 (43·2%) had possible neuropathic discomfort. s-LANSS score was significantly higher in DFU group (8·1 ± 7·7 versus 4·7 ± 4·6; P = 0·04). However, there was no difference in the perception of pain in 10-point Likert scale (3·9 ± 3·6 versus 3·3 ± 3·0; P = NS) between these two groups. This study suggests that subjects with DFU may suffer from PDPN, but do not perceive it. Further studies are needed to assess if treatment of PDPN in these subjects is beneficial.     

Single nucleotide variations in the development of diabetic foot ulcer: A narrative review

Diabetes mellitus has become a global health problem, and the number of patients with diabetic foot ulcers (DFU) is rapidly increasing. Currently, DFU still poses great challenges to physicians, as the treatment is complex, with high risks of infection, recurrence, limb amputation, and even death. Therefore, a comprehensive understanding of DFU pathogenesis is of great importance. In this review, we summarized recent findings regarding the DFU development from the perspective of single-nucleotide variations (SNVs). Studies have shown that SNVs located in the genes encoding C-reactive protein, interleukin-6, tumor necrosis factor-alpha, stromal cell-derived factor-1, vascular endothelial growth factor, nuclear factor erythroid-2-related factor 2, sirtuin 1, intercellular adhesion molecule 1, monocyte chemoattractant protein-1, endothelial nitric oxide synthase, heat shock protein 70, hypoxia inducible factor 1 alpha, lysyl oxidase, intelectin 1, mitogen-activated protein kinase 14, toll-like receptors, osteoprotegerin, vitamin D receptor, and fibrinogen may be associated with the development of DFU. However, considering the limitations of the present investigations, future multi-center studies with larger sample sizes, as well as in-depth mechanistic research are warranted.     

Diabetic foot disease:From the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities

The burden of diabetic foot disease(DFD) is expected to increase in the future. The incidence of DFD is still rising due to the high prevalence of DFD predisposing factors. DFD is multifactorial in nature; however most of the diabetic foot amputations are preceded by foot ulceration. Diabetic peripheral neuropathy(DPN) is a major risk factor for foot ulceration. DPN leads to loss of protective sensation resulting in continuous unconscious traumas. Patient education and detection of high risk foot are essential for the prevention of foot ulceration and amputation. Proper assessment of the diabetic foot ulceration and appropriate management ensure better prognosis. Management is based on revascularization procedures, wound debridement, treatment of infection and ulcer offloading. Management and type of dressing applied are tailored according to the type of wound and the foot condition. The scope of this review paper is to describe the diabetic foot syndrome starting from the evaluation of the foot at risk for ulceration, up to the new treatment modalities.